(R)-Darifenacin-d4
| Product Name | (R)-Darifenacin-d4 |
|---|---|
| Alternate Names | Darifenacin Stable Isotopes, Stable Isotopes of Darifenacin |
| CAT No. | CS-T-73395 |
| CAS No. | 1261734-81-9 |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Darifenacin |
| Smileys | NC(C([C@@H]1CN(C([2H])([2H])C([2H])([2H])C2=CC=C(OCC3)C3=C2)CC1)(C4=CC=CC=C4)C5=CC=CC=C5)=O |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
(R)-Darifenacin-d4 is a deuterated form of the medication Darifenacin, which is used to treat symptoms of an overactive bladder. The medication works by blocking the muscarinic receptors in the bladder, which helps to reduce involuntary contractions and increase the bladder's capacity.
Chemically, (R)-Darifenacin-d4 is a selective M3 muscarinic receptor antagonist. It has a molecular weight of 480.63 g/mol and a chemical formula of C28H26D4N3O2S. It is typically administered orally in tablet form, with a recommended dosage of 7.5mg once daily.
In terms of usage, (R)-Darifenacin-d4 is recommended for adults who experience symptoms of an overactive bladder, such as urinary urgency, frequency, and urge incontinence. It is not recommended for individuals who have urinary retention or gastric retention, as the medication can worsen these conditions.
There are some potential side effects associated with (R)-Darifenacin-d4, including dry mouth, constipation, blurred vision, and difficulty urinating. It is important for patients to discuss these potential side effects with their healthcare provider before starting the medication. Additionally, patients should inform their healthcare provider of any other medications they are taking, as certain medications can interact with (R)-Darifenacin-d4 and increase the risk of side effects.
Get an Instant Quote
Related Compounds
Darifenacin D4 hydrochloride | Darifenacin D4 Hydrobromide | rac Darifenacin-d4 | Darifenacin D4 |